MDGEF (Medigene AG) Marketable Securities: $0.00 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDGEF Medigene AG MDGEF
12 GF Score
Price $2.59
View Full Analysis

What is Medigene AG Marketable Securities?

Medigene AG MDGEF 12 Marketable Securities is $0.00 Mil as of Jun. 2024. GuruFocus rates MDGEF with a GF Score™ of 12/100.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Medigene AG's Marketable Securities for the quarter that ended in Jun. 2024 was $0.00 Mil.

Medigene AG's annual Marketable Securities increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($11.65 Mil) but then declined from Dec. 2022 ($11.65 Mil) to Dec. 2023 ($8.72 Mil).

Medigene AG  (OTCPK:MDGEF) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Medigene AG Marketable Securities Related Terms

Medigene AG Marketable Securities Historical Data

* Premium members only.

The historical data trend for Medigene AG's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigene AG Marketable Securities Chart

Medigene AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.22 0.00 0.00 11.65 8.72

Medigene AG Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 11.65 0.00 8.72 0.00
MDGEF
12GF Score
Medigene AG MDGEF
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigene AG Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Medigene AG (MDGEF) has a Marketable Securities of $0.00 Mil as of Jun. 2024. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Medigene AG and its competitors.
Is Medigene AG's Marketable Securities too high?
Medigene AG's current Marketable Securities is $0.00 Mil. Overall, Medigene AG has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Medigene AG's Marketable Securities compare to VRTX and REGN?
Medigene AG's Marketable Securities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Medigene AG and its competitors. Medigene AG's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigene AG stock overvalued right now?
Medigene AG (MDGEF) has a current Marketable Securities of $0.00 Mil. The current Marketable Securities is $0.00 Mil. Medigene AG's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Medigene AG (MDGEF), the current Marketable Securities is $0.00 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medigene AG Business Description

Address Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
12GF Score

Get the complete analysis for MDGEF

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.59
Price